SELDI

NEW YORK (GenomeWeb News) – Vermillion today announced that all four non-contingent contract claims with Bio-Rad Laboratories stemming from Vermillion's sale of its proteomics business

ProteoMonitor spoke to Cristobal Belda-Iniesta, head of the Biomarkers and Experimental Therapeutics for Cancer Group at Madrid's University Hospital La Paz, about his work applying proteomics to guide cancer therapy.

The patent's claims cover biomarker combinations for the diagnosis and management of Alzheimer's disease and their measurement by methods including mass spectrometry and immunoassay.

The system, called Lucid Proteomics, combining Bio-Rad's SELDI-based array technology with Bruker's ultrafleXtreme MALDI-TOF/TOF instrument, is expected to hit the market in late summer or early fall, and is the first fruit of a co-marketing and co-development collaboration between the two firms announced a month ago.

The company remains in business and continues work to get FDA approval for its ovarian tumor triage diagnostic. In its filing, the company said it had assets of about $7.2 million and liabilities of approximately $32 million as of Sept. 30, 2008.

In a competitive field where deals linking two mass-spec technologies from different vendors are unusual, the partnership could help Bio-Rad make relevant a technology that has failed to capture the interest of the research community.

John Mendelsohn, a former president of the University of Texas MD Anderson Cancer Center, has died, the New York Times reports.

Chinese state news agency Xinhua reports that a preliminary investigation has found He Jiankui performed his gene-editing work illegally.

Identical twins receive different estimates of ancestry from the same direct-to-consumer genetic testing firms, CBC reports.

In PNAS this week: chromosomal features of maize, adaptations in the vinous-throated parrotbill, and more.